Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

183 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
T cell responses to repeated SARS-CoV-2 vaccination and breakthrough infections in patients on TNF inhibitor treatment: a prospective cohort study.
Wolf AS, Bjørlykke KH, Ørbo HS, Bhandari S, Solum G, Kjønstad IF, Jyssum I, Nygaard UC, Kristoffersen AB, Christensen IE, Josefsson SE, Lund KP, Chopra A, Osen JR, Chaban V, Tveter AT, Sexton J, Kvien TK, Jahnsen J, Haavardsholm EA, Grødeland G, Vaage JT, Provan SA, Kared H, Lund-Johansen F, Munthe LA, Syversen SW, Goll GL, Jørgensen KK, Mjaaland S. Wolf AS, et al. Among authors: jahnsen j. EBioMedicine. 2024 Oct;108:105317. doi: 10.1016/j.ebiom.2024.105317. Epub 2024 Sep 10. EBioMedicine. 2024. PMID: 39260039 Free PMC article.
Immunogenicity and safety of a three-dose SARS-CoV-2 vaccination strategy in patients with immune-mediated inflammatory diseases on immunosuppressive therapy.
Syversen SW, Jyssum I, Tveter AT, Sexton J, Christensen IE, Tran TT, Bjørlykke KH, Mjaaland S, Warren DJ, Kvien TK, Chopra A, Kro GB, Jahnsen J, Munthe LA, Haavardsholm EA, Grødeland G, Vaage JT, Provan SA, Jørgensen KK, Goll GL. Syversen SW, et al. Among authors: jahnsen j. RMD Open. 2022 Nov;8(2):e002417. doi: 10.1136/rmdopen-2022-002417. RMD Open. 2022. PMID: 36328399 Free PMC article.
Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study.
Bjørlykke KH, Ørbo HS, Tveter AT, Jyssum I, Sexton J, Tran TT, Christensen IE, Kro GB, Kvien TK, Jahnsen J, Munthe LA, Chopra A, Warren DJ, Mjaaland S, Haavardsholm EA, Grødeland G, Provan SA, Vaage JT, Syversen SW, Goll GL, Jørgensen KK. Bjørlykke KH, et al. Among authors: jahnsen j. Lancet Rheumatol. 2023 Jan;5(1):e36-e46. doi: 10.1016/S2665-9913(22)00330-7. Epub 2022 Nov 16. Lancet Rheumatol. 2023. PMID: 36415604 Free PMC article.
HLA-DQ2 is associated with anti-drug antibody formation to infliximab in patients with immune-mediated inflammatory diseases.
Brun MK, Bjørlykke KH, Viken MK, Stenvik GE, Klaasen RA, Gehin JE, Warren DJ, Sexton J, Sandanger Ø, Kvien TK, Mørk C, Haavardsholm EA, Jahnsen J, Goll GL, Lie BA, Bolstad N, Jørgensen KK, Syversen SW. Brun MK, et al. Among authors: jahnsen j. J Intern Med. 2023 May;293(5):648-655. doi: 10.1111/joim.13616. Epub 2023 Feb 26. J Intern Med. 2023. PMID: 36843323
Clinical consequences of infliximab immunogenicity and the effect of proactive therapeutic drug monitoring: exploratory analyses of the randomised, controlled NOR-DRUM trials.
Brun MK, Gehin JE, Bjørlykke KH, Warren DJ, Klaasen RA, Sexton J, Sandanger Ø, Kvien TK, Mørk C, Jahnsen J, Bolstad N, Jørgensen KK, Haavardsholm EA, Goll GL, Syversen SW. Brun MK, et al. Among authors: jahnsen j. Lancet Rheumatol. 2024 Apr;6(4):e226-e236. doi: 10.1016/S2665-9913(23)00341-7. Epub 2024 Feb 22. Lancet Rheumatol. 2024. PMID: 38402891 Clinical Trial.
Incidence and outcome of COVID-19 following vaccine and hybrid immunity in patients on immunosuppressive therapy: identification of protective post-immunisation anti-RBD antibody levels in a prospective cohort study.
Ørbo HS, Bjørlykke KH, Sexton J, Jyssum I, Tveter AT, Christensen IE, Mjaaland S, Kvien TK, Grødeland G, Kro GB, Jahnsen J, Haavardsholm EA, Munthe LA, Provan SA, Vaage JT, Goll GL, Jørgensen KK, Syversen SW. Ørbo HS, et al. Among authors: jahnsen j. RMD Open. 2024 Apr 9;10(2):e003545. doi: 10.1136/rmdopen-2023-003545. RMD Open. 2024. PMID: 38599653 Free PMC article.
Humoral and cellular responses to a fifth bivalent SARS-CoV-2 vaccine dose in patients with immune-mediated inflammatory diseases on tumour necrosis factor inhibitors: a prospective cohort study.
Ørbo HS, de Matos Kasahara T, Wolf AS, Bjørlykke KH, Sexton J, Jyssum I, Tveter AT, Solum G, Kjønstad IF, Bhandari S, Christensen IE, Kvien TK, Lind A, Kared H, Jahnsen J, Haavardsholm EA, Munthe LA, Provan SA, Vaage JT, Mjaaland S, Syversen SW, Jørgensen KK, Grødeland G, Goll GL. Ørbo HS, et al. Among authors: jahnsen j. Lancet Reg Health Eur. 2024 Nov 15;48:101121. doi: 10.1016/j.lanepe.2024.101121. eCollection 2025 Jan. Lancet Reg Health Eur. 2024. PMID: 39624496 Free PMC article.
Deficient SARS-CoV-2 hybrid immunity during inflammatory bowel disease.
Alirezaylavasani A, Egner IM, Dahl B, Chopra A, de Matos Kasahara T, Goll GL, Jahnsen J, Grødeland G, Vaage JT, Lund-Johansen F, Holter JC, Halvorsen B, Jørgensen KK, Munthe LA, Kared H. Alirezaylavasani A, et al. Among authors: jahnsen j. Clin Immunol. 2024 Dec 5;271:110404. doi: 10.1016/j.clim.2024.110404. Online ahead of print. Clin Immunol. 2024. PMID: 39645159 Free article.
183 results